Omics Global Solutions (OGS) borns as a company whose objective is to be the platform for development and launch of products related to "omics" sciences (proteomics, genomics, metabolomics, etc.) associated with innovative projects that have an impact on the lives of patients, their caregivers and medical professionals. Located in Puerto Rico (USA), it's first milestone is the development and commercialization of one ELISA assay (INNOVATIO ND2™) based on IP Protected algorithm, for the risk identification of Diabetic Kidney Disease (DKD) using PromarkerD™ platform . Being a Biotechnology company with development and commercial skills Omics is always open and seeking for strategic alliances for novel technologies with clear impact in the diagnostic field.